SEO URLwww.firestrike.ai/deals/veradermics-lilly-acquisition-2026

acquisitionAnnounced · Feb 4, 2026biopharmaSource · Unverified ReportsArticle · Factual

Veradermics · Lilly

Lilly acquires Veradermics

David Najork · Founding Software Engineer

Announced Feb 4, 2026 · Updated Apr 29, 2026 · 1 min read

ShareX LinkedIn Email

Deal value

$30M

Target

Veradermics

NYSE:MANE · New Haven, Connecticut

Acquirer

Lilly

Financial Stake

Status

Pending

Lilly agreed to acquire Veradermics. Reported deal value: $30M. Status: Pending. Sector: biopharma. Target headquarters context: New Haven, Connecticut, United States.

This page summarizes publicly available information about the transaction as of 2026-02-04. Figures and status may change as filings and press coverage update.

Veradermics IPO Pops Above Range as Eli Lilly Lines Up a 5% Stake Play by NEW YORK, Feb 4, 2026, 07:08 Veradermics set its upsized IPO price at $17 a share, pulling in roughly $256.3 million before expenses A filing revealed Eli Lilly intent to acquire as much as 4.9% of post- IPO shares Veradermics is set to begin trading on the NYSE under the ticker MANE” starting Feb

Deal timeline

Announced

Feb 4, 2026 · ts2.tech

Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.

Sector context

This transaction is classified in biopharma with a reported deal value of $30M. Figures and status may change as sources update.

Sources: ts2.tech · Primary article · FireStrike proprietary index